SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug NX-5948 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in about 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after treatment with BTK and BCL-2 inhibitors. The main goal is to see if the drug …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
New Triple-Drug attack aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) can make cancer cells undetectable in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who need treatment for the first…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo aims to deeply suppress blood cancer in relapsed patients
Disease control Recruiting nowThis study tests whether combining two targeted drugs, zanubrutinib and venetoclax, can deeply suppress chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people whose cancer returned after prior treatment. About 45 adults who have not used these specific d…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Promising drug offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a drug called venetoclax in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 110 participants will receive the drug to see if it shrinks their cancer. The goal is to…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New study explores immune effects of CLL drug in untreated patients
Knowledge-focused Recruiting nowThis early-phase study looks at how the drug pirtobrutinib changes immune cells in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 30 adults will take pirtobrutinib daily and have blood and lymph node tests to track immune syste…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: EARLY_PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC
-
New study tracks daily life impact of CLL and SLL treatments
Knowledge-focused Recruiting nowThis study follows 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for 2 years to see how their quality of life, fatigue, and symptoms change during treatment. Researchers compare two common treatment types to help future patients know what …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated May 07, 2026 18:42 UTC